

Polymers for Better Living[™]

Kevin Matthews, CEO John Shaw, President US

June 2018

Cautionary statement

The information contained in this confidential document ("Presentation") has been prepared by Itaconix Plc (the "Company"). It has not been fully verified and is subject to material updating, revision and further amendment. This Presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000 ("FSMA") and therefore it is being delivered for information purposes only to a very limited number of persons and companies who are persons who have professional experience in matters relating to investments and who fall within the category of person set out in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or are high net worth companies within the meaning set out in Article 49 of the Order or are otherwise permitted to receive it. Any other person who receives this Presentation should not rely or act upon it. By accepting this Presentation and not immediately returning it, the recipient represents and warrants that they are a person who falls within the above description of persons entitled to receive the Presentation. This Presentation is not to be disclosed to any other person or used for any other purpose.

Please note that the information in this Presentation has yet to be announced or otherwise made public and as such constitutes inside information for the purposes of Article 14 of the Market Abuse Regulation (596/2014/EU) and the Criminal Justice Act 1993. You should not therefore deal in any way in the securities of the Company until after the formal release of an announcement by the Company as to do so may result in civil and/or criminal liability.

Nplus1 Singer Advisory LLP ("N+1") is acting in the provision of corporate finance business to the Company, within the meaning of the Financial Conduct Authority's Conduct of Business Sourcebook ("COBS"), and no-one else in connection with the proposals contained in this Presentation. Accordingly, recipients should note that N+1 is neither advising nor treating as a client any other person and will not be responsible to anyone other than the Company for providing the protections afforded to clients of N+1 under the COBS nor for providing advice in relation to the proposals contained in this Presentation.

While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss. howsoever arising, from the use of this Presentation.

This Presentation may contain forward-looking statements that involve substantial risks and uncertainties, and actual results and developments may differ materially from those expressed or implied by these statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial condition, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. These forward-looking statements speak only as of the date of this Presentation and the Company does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Presentation.

Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.

This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. In particular, this Presentation does not constitute an offer or invitation to subscribe for or purchase any securities and neither this Presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.

Neither this Presentation nor any copy of it may be (a) taken or transmitted into Australia, New Zealand, Canada, Japan, the Republic of Ireland, the Republic of South Africa or the United States of America (each a "Restricted Territory"), their territories or possessions; (b) distributed to any U.S. person (as defined in Regulation S under the United States Securities Act of 1933 (as amended)) or (c) distributed to any individual outside a Restricted Territory who is a resident thereof in any such case for the purpose of offer for sale or solicitation or invitation to buy or subscribe any securities or in the context where its distribution may be construed as such offer, solicitation or invitation, in any such case except in compliance with any applicable exemption. The distribution of this document in or to persons subject to other jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the relevant jurisdiction.



Management Team







Kevin Matthews (CEO)

John R. Shaw (President US)

Robin Cridland (CFO)

Announced consolidation into the US requires realignment of management team subject to successful fundraise

Kevin Matthews Executive Chairman

John R. Shaw CEO Robin Cridland
Will step down at end July



Investment Case

- 1. Three main products for major unmet needs with proven performance
- 2. Strong pipeline of active customer projects
- 3. Production capacity at US plant up to \$25 million revenue*
- Breakthrough products →Interest from market leaders →
 Collaborations

Active Itaconix Projects = \$30 Million Annual Revenue Potential*



^{*} Management Estimates

Itaconix - Bio-Based Ingredients for Unmet Needs

Key Performance Ingredients for Success of Customer Products

- Leader in novel bio-based polymers based on itaconic acid
- Itaconic acid is a renewable chemical produced by fermentation
- Established proprietary process with breakthrough economics
- Offer enhanced product performance at a competitive price

Leading Solutions for Unmet Formulation Needs in Major Markets



Non-Phosphate Detergents

- North America, Europe
- Emerging markets
- Scaling with AkzoNobel



Malodour Control

- Home care
- Scaling with Croda



Bio-Based Hair Styling

- Pumps, sprays, gels
- Worldwide opportunity
- Distributors in 14 countries



Malodour – Why the Big Stink over ZINADOR™?

Key Odour Trend: Neutralise, Don't Just Mask

- Formulators want to neutralise odours rather than only mask them with fragrance.
- Ingredient in carpet cleaners, air fresheners, fabric care, surface cleaners, and pet care.

ZINADOR™: Zinc with Benefits

- Zinc is known and used to neutralise odours.
- Zinc ricinoleate and other zinc forms are well-established competitors to cyclodextrins (Febreze) and surfactants (ex: Croda's Forestall).
- ZINADOR™ offers performance benefits and ease-of-use over zinc ricinoleate.

Croda + ZINADOR™: Great Fit, Smart Partnering to Go Global

- Itaconix evidenced potential with first sales to customers before partnering.
- Croda has >30 years experience in odour market, but no zinc-based product.
- New sales in North America, Europe, Russia, Middle East and India.
- Customer projects advancing; new consumer brand products expected in 2019.





Hair Styling - Let's go Natural


Key Need: A Bio-Based Polymer that Holds Styles

- Personal care is on the leading edge for bio-based product claims. Consumers will choose and pay price premiums for bio-based products.
- \$440 million hair styling market is demanding due to immediate and extended tactile sense of performance.
- Certifications (e.g. COSMOS™) limit "green washing".

RevCare™ NE: Performance + Bio-Based

- Competes with petroleum-based market leaders for styling, heat protection, frizz control.
- Only hair styling polymer with COSMOS™ approval.
- RevCare NE 100S: \$130 million* accessible market.
- Scaling globally through direct sales to major brands and distributors in 14 countries.
- Already in consumer products; repeat orders; global pipeline of active projects.







Non-Phosphate Detergents – Established Use

Phosphates: Bans Require Reformulation

- Europe & North America have expanded bans; limits likely to emerge in Asia.
- Market still seeking comparable products.
- Itaconix polymers have multi-functionality similar to phosphates.

2009 to 2015: Success with Direct Engagement

- Direct sales of Itaconix® DSP™ since 2009 for automatic dish & laundry detergents in Europe & North America.
- Active detergent lab in US for formulating & reformulating customer products.


2016 to Today: New Products for Major Needs

- Expanding ability to modify polymers for specific customer needs.
- Itaconix® CHT™ for automatic dishwashers.

Leading Alternatives in Powder Detergents

| Performance | Phosphate | Itaconix | Citrate | MGDA |
|------------------|-----------|----------|---------|------|
| Chelation | ٧ | V | ٧ | ٧ |
| Scale inhibition | ٧ | V | | |


Steady Success with Direct Selling Efforts





Pressure for Options = Itaconix® CHT™ Opportunity

 First generation powder EU non-phosphate automatic dishwash detergents rely on MGDA granulate for premium builder performance, but are costly



2. BASF is sole source of MGDA granulate with patented position

| Major ADW Builders | Granulate Form | Liquid Form | | |
|-----------------------|--------------------------------------|-----------------------------|--|--|
| Scale Inhibitors | | | | |
| Acrylate polymers | BASF, Dow | , Others | | |
| Chelates | | | | |
| Citrate | Tate & Lyle Jungbunzlauer, Others | | | |
| GLDA | Poor dry stability | AkzoNobel Others | | |
| MGDA | BASF only | BASF AkzoNobel Others | | |

Detergent note:

- Builders are in formulas to lessen adverse effects of hard water on cleaning performance.
- Soda ash is a common base builder used with the above.
- Other builder additives include amino polycarboxylates other than MGDA (ex: GLDA, NTA, EDTA, IDS, EDDS), carboxymethyl inulin, polyaspartic acid, and phosphonates.

3. Brands place pressure on suppliers for alternatives to MGDA granulate for better cost, performance, and sourcing.

Itaconix® CHT™122

 Itaconix responds to brand and industry interest in Itaconix DSP with optimised version for automatic dishwash detergents



Competitors seek alternatives

to MGDA

granulate

Next Generation Automatic Dishwasher Pods

Automatic Dishwasher Tablet & Pod Market

- Europe 15 billion units*
- North America 15 billion units*
- Major, private-label, and specialty brands at risk of losing market share with current formulas.

\$135 Million Potential* For Itaconix® CHT™

- Use 1 gram per pod
- Volume 30,000 metric tons
- Potential \$135 million


Building Traction with Full Pipeline

- Four new products so far this year.
- Nine active projects with major, specialty, and private-label brands.
- Scaling marketing with AkzoNobel Chelates

New Compact Automatic Dishwasher Pod



US Automatic Dish Pod Ingredient Cost*





^{*} Management Estimates

Proprietary Capacity in Place to Grow

Reliable Fulfillment Ready for Demand


- Commercial production since 2009
- Plant expansion completed in 2017
- Current site with debottlenecking can generate up to \$25 million revenues*



* Management Estimates

Proprietary Process with Low Capital Needs

- Breakthrough economics
- Debottlenecking cost estimated at <\$500,000*
- Protected by process and composition patents





New Performance Ingredients for Unmet Needs

Demand for New Formulations

Itaconix Patented Products

Safety

Better human or environmental outcomes

Phosphate replacement in detergent

Itaconix® DSP™

Itaconix[®] CHT ™

Performance

Better product outcomes at comparable or lower cost

Malodour control in home and personal care

Itaconix ® ZINADOR ™

Sustainability

Less reliance on petroleum

Bio-based hair styling

RevCare™ NE / HP



Poised for Growth: Aligned with Market Needs

Products and routes to revenue growth with market leaders

- Positive commercial position with proven products
- Reduced cost base with aim to reach profitability sooner
- Commercial activities consolidated into US operations, while retaining key UK personnel

Management & Board aligned with US operations, subject to fundraise

- Bryan Dobson moves from Chairman to Independent NED until a suitable replacement can be found
- Kevin Matthews assumes role as Executive Chairman
- John Shaw steps into the role of CEO, located in New Hampshire
- After 10 years dedicated to the company and with the main operations transitioning to the US, Robin Cridland will step down as CFO at the end of July 2018, handing over to an interim CFO at that time
- Julian Heslop (NED) will also step down in due course once a suitable replacement can be found



Fundraising Statistics, Incentives and Timetable

Fundraising statistics and use of proceeds

- Firm placing via ABB and subscription of up to £5m
- Additional open offer (with excess application facility) of up to £1m
- Funds to be used for commercial development and working capital

Alignment of incentives – see Appendix for details

Issue of 15 million new shares and extension of performance based contingent consideration

Timetable

- Roadshow ends: 26 June 2018
- Preliminary results and ABB announced: 28 June 2018
- General Meeting to approve fundraise: 18 July 2018
- New shares admitted to AIM/settlement: 19 July 2018



Why Invest Now?

- 1. Three breakthrough products for major unmet needs
- 2. First sales prove customer value
- 3. Production capacity in place to grow
- 4. Significant near-term growth potential from direct sales efforts
- 5. Collaborators adding more potential for worldwide revenues
- 6. Key issues addressed:
 - Cash for growth from fundraise
 - Reduced cost base
 - Merger Agreement



Appendices

- Management team
- Board of Directors
- Summary consolidated financial statements
- Alignment of incentives
- Sustainability trend in consumer products



Management Team



Kevin Matthews (CEO)
Internationally experienced public and private company director
Experienced strategic leader with strong commercial acumen. NED at Low & Bonar Plc. Formerly CEO
Isogenica Ltd and Oxonica Plc, NED at Elementis Plc




Robin Cridland (CFO)
Experienced In Finance and M&A
20+ years of pharma/tech business
development, corporate development and
finance experience:
GSK merger, Renovo IPO,
Shire licence/investment, Revolymer IPO.
NED of Eden Research plc



John Shaw
President ITX US
Itaconix co-founder & lead investor
30+ years turning chemical and medical
technologies into growth products/businesses;
co-chair BIO Bio-Based Products Working Group;
frequent speaker on renewable chemicals



Experienced Board



Bryan Dobson Chairman Chairman of Applied Graphene Materials Plc 30+ years in chemicals industry including ICI and Croda



Julian Heslop - NED/Audit Chair Previously CFO of GlaxoSmithKline Senior finance roles at Grand Metropolitan and Imperial Brewing and Leisure





Jim Barber - NED
Previously CEO of Metabolix Inc.
Senior commercial roles within
Albermarle group and other
chemicals businesses.
Representative of Itaconix Corp.
Shareholders (pre-acquisition).



Mike Townend - NED 20+ years experience in equity capital markets including Lehman Brothers. Representative of IP Group.



Summary Consolidated Financial Statements

| GBPm | Income Statement Extracts - Continuing Operations | 2017 | 2016 |
|------|---|-------|------|
| | Revenue | 0.6 | 0.3 |
| | Cost of Sales | -0.3 | -0.2 |
| | Gross Profit | 0.2 | 0.1 |
| | Other operating income | 0.1 | 0.0 |
| | Administrative expenses | -5.5 | -5.3 |
| | Group Operating Loss | -5.2 | -5.2 |
| | Finance income | 0.0 | 0.1 |
| | Exceptional items: | | |
| | Income on revaluation of contigent consideration | 2.5 | |
| | Expense on impairment of intangible assets | -9.0 | |
| | Share of loss of associate | -0.2 | -0.5 |
| | Loss before tax | -11.9 | -5.6 |
| | Release of deferred tax liability | 1.2 | |
| | Taxation credits | 0.5 | 0.5 |
| | Loss for the year | -10.2 | -5.1 |

NB: Statement summaries may not cast due to roundings

Note that the 2017 results will be announced immediately prior to the fundraise



Summary Consolidated Financial Statements

| GBPm | Balance Sheet Extracts | 2017 | 2016 | | 2017 | 2016 |
|-----------|-------------------------------------|-----------|------|------------------------------|-------|-------|
| | Non-current assets | | | Equity | | |
| | Property, plant and equipment | 1.0 | 0.8 | Share capital | 0.8 | 0.8 |
| | Intangible assets | | 10.1 | Share premium | 28.6 | 28.6 |
| | Associate | | 0.1 | Retained earnings | -53.1 | -42.9 |
| | | 1.0 | 11.1 | Other reserves | 27.7 | 28.0 |
| | | | | | 4.0 | 14.5 |
| | Current assets | | | | | |
| | Inventory | 0.3 | 0.2 | Non-current liabilities | | |
| | Receivables | 0.7 | 0.8 | Provisions | -0.6 | -3.4 |
| | Cash and cash equivalents | 3.6 | 8.8 | Deferred tax liability | | -1.5 |
| | | 4.6 | 9.8 | | -0.6 | -4.9 |
| | TOTAL ASSETS | 5.6 | 20.9 | Current liabilities | | |
| | | | | Payables | 1.0 | 1.6 |
| NB: State | ement summaries may not cast due to | roundings | | TOTAL EQUITY AND LIABILITIES | 5.6 | 20.9 |



Summary Consolidated Financial Statements

| GBPm | Cash Flow Statement Extracts | 2017 | 2016 |
|------|--|------|------|
| | Cash flow from continuing operating activities | -4.7 | -3.5 |
| | Cash flow from discontinued operating activities | | -1.3 |
| | | -4.7 | -4.7 |
| | Cash flow from investing activities | | |
| | Interest received | 0.0 | 0.1 |
| | Purchase of PPE | -0.4 | -0.5 |
| | Acquisition of subsidiary | | -2.0 |
| | Investment in associate | -0.1 | |
| | Funds withdrawn from deposits | | 7.0 |
| | | -0.5 | 4.5 |
| | Cash flow from financing activities | | |
| | Cash from share issues net of costs | 0.0 | 5.5 |
| | Cash loaned to associate | 0.0 | |
| | | 0.0 | 5.5 |
| | Net cash flow | -5.2 | 5.3 |
| | Cash at start of the year | 8.8 | 3.5 |
| | Cash at end of the year | 3.6 | 8.8 |

NB: Statement summaries may not cast due to roundings



Alignment of Incentives

Management incentives are aligned with growth and shareholders' goals, subject to successful fundraise:

- John Shaw (CEO designate) and Yvon Durant (CTO) receive standard management contracts, with suspension of cash bonus and LTIP to end of 2020, in place of current fixed management contracts with incentives.
- John Shaw, Yvon Durant, and original Itaconix Corp shareholder release restrictive covenants in the 2016 Merger Agreement.
- In return for replacing contracts, suspending incentives, and releasing covenants, John Shaw, Yvon Durant, and original Itaconix Corp shareholder receive 15 million new shares issued at completion of fundraise and retain potential to earn up to \$6m paid in future shares at future share prices based on revenues above \$3m and up to \$15m by the end of 2022.



Sustainability – Mega Trend of Our Generation

L'ORÉAL

L'Oréal: Sustainability targets change the way products are designed

By 2020, L'Oréal is committed to improve the environmental or social profile of 100% of its new or renovated products. This means that all consumers around the world can be assured that every new L'Oréal product they buy has improved its impact on the environment and on society.

Itaconix Partners

P&G



Our Long-Term Product End-Points

- Using 100% renewable or recycled materials for all products and packaging
- · Having zero consumer waste go to landfills
- Designing products to delight consumers while maximizing the conservation of resources

CRODA

Sustainability is the thread that connects every aspect of our Business

In 2016, we have continued to lead our industry with almost two thirds of our raw materials being derived from natural and renewable resources.



AkzoNobel, Arkema, BASF, Bayer Clariant, DSM, DuPont, Evonik, Henkel, IFF, Lanxess, Solvay, Wacker

Itaconix's bio-based polymers fit into customers' global agendas, with products ideally positioned to play a significant role in improving performance with sustainability

